IL134480A0 - Kay - an immune system protein and dna sequences encoding the same - Google Patents

Kay - an immune system protein and dna sequences encoding the same

Info

Publication number
IL134480A0
IL134480A0 IL13448098A IL13448098A IL134480A0 IL 134480 A0 IL134480 A0 IL 134480A0 IL 13448098 A IL13448098 A IL 13448098A IL 13448098 A IL13448098 A IL 13448098A IL 134480 A0 IL134480 A0 IL 134480A0
Authority
IL
Israel
Prior art keywords
kay
same
immune system
dna sequences
sequences encoding
Prior art date
Application number
IL13448098A
Other languages
English (en)
Original Assignee
Apotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotech Sa filed Critical Apotech Sa
Publication of IL134480A0 publication Critical patent/IL134480A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL13448098A 1997-09-12 1998-09-11 Kay - an immune system protein and dna sequences encoding the same IL134480A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Publications (1)

Publication Number Publication Date
IL134480A0 true IL134480A0 (en) 2001-04-30

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13448098A IL134480A0 (en) 1997-09-12 1998-09-11 Kay - an immune system protein and dna sequences encoding the same

Country Status (17)

Country Link
EP (1) EP1012270A2 (de)
JP (1) JP2001515711A (de)
KR (1) KR20010023892A (de)
CN (1) CN1269832A (de)
AU (1) AU9315298A (de)
BR (1) BR9812433A (de)
CA (1) CA2303424A1 (de)
EA (1) EA200000311A1 (de)
EE (1) EE200000148A (de)
HU (1) HUP0004034A3 (de)
IL (1) IL134480A0 (de)
IS (1) IS5375A (de)
NO (1) NO20001240L (de)
PL (1) PL339740A1 (de)
SK (1) SK3532000A3 (de)
TR (1) TR200000654T2 (de)
WO (1) WO1999012964A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
CA2310987A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
IL144202A0 (en) 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
CA2363112A1 (en) * 1999-02-23 2000-08-31 Craig A. Rosen Neutrokine-alpha and neutrokine-alpha splice variant
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AU4986700A (en) 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
CN100447244C (zh) 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2897626C (en) 2000-02-11 2020-03-24 Biogen Ma Inc. Heterologous polypeptide of the tnf family
WO2001087977A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002018620A2 (en) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
DK1385882T3 (da) 2001-05-11 2008-02-11 Amgen Inc Peptider og relaterede molekyler, der binder til TALL-1
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
JP2007526220A (ja) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
JP2007509064A (ja) 2003-10-20 2007-04-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｂａｆｆアンタゴニストのための治療養生法
US20070249530A1 (en) * 2004-01-29 2007-10-25 Genentech, Inc. Bcma Polypeptides and Uses Thereof
BRPI0516297A (pt) 2004-10-05 2008-09-02 Genentech Inc métodos de tratamento de vasculite e artigos de fabricação
EP2332563A3 (de) 2004-10-13 2013-03-13 The Washington University Verwendung von BAFF zur Behandlung von Sepsis
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EP1922080A2 (de) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Verfahren zur behandlung von b-zell-malignomen mittels taci-ig-fusionsmolekül
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
BRPI0711823A2 (pt) 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
MX353143B (es) 2011-02-28 2017-12-20 Genentech Inc Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
WO2015155332A1 (en) 2014-04-11 2015-10-15 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
PT939804E (pt) * 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5

Also Published As

Publication number Publication date
WO1999012964A2 (en) 1999-03-18
PL339740A1 (en) 2001-01-02
HUP0004034A3 (en) 2002-08-28
SK3532000A3 (en) 2001-12-03
JP2001515711A (ja) 2001-09-25
EP1012270A2 (de) 2000-06-28
KR20010023892A (ko) 2001-03-26
EA200000311A1 (ru) 2000-10-30
EE200000148A (et) 2001-02-15
BR9812433A (pt) 2000-09-26
NO20001240L (no) 2000-05-10
CA2303424A1 (en) 1999-03-18
NO20001240D0 (no) 2000-03-09
TR200000654T2 (tr) 2000-07-21
AU9315298A (en) 1999-03-29
IS5375A (is) 2000-02-11
HUP0004034A2 (en) 2001-03-28
WO1999012964A3 (en) 1999-05-27
CN1269832A (zh) 2000-10-11

Similar Documents

Publication Publication Date Title
IL134480A0 (en) Kay - an immune system protein and dna sequences encoding the same
IL197834A0 (en) Polypeptides and nucleic acids encoding the same
PT1490386E (pt) Novos polipéptidos e ácidos nucleicos que os codificam
IL147145A0 (en) ANTI-αvβ3 RECOMBINANT HUMAN ANTIBODIES AND NUCLEIC ACIDS ENCODING THE SAME
GB9726398D0 (en) Polypeptide and coding sequences
PL329160A1 (en) Novel phytase and phytase encoding gene
GB9310472D0 (en) Phenylalanine-free protein and dna coding thereof
GB9408717D0 (en) DNA sequences
GB9719879D0 (en) Protein
IL132236A0 (en) Beta - amyloid peptide - binding proteins and polynucleotides encoding the same
GB9421093D0 (en) Hippocampus-associated proteins, DNA sequences coding therefore and uses thereof
EP0729975A4 (de) Ecdn - protein und dafuer kodeierende dna
AU8772598A (en) Dna encoding the human synapsin iii gene and uses thereof
ZA988460B (en) Polypeptides and nucleic acids encoding the same
AU6844596A (en) Nucleotide sequence encoding the cd33-like protein
IL122626A0 (en) Nucleic acids encoding hev structural proteins hev structural proteins encoded thereby and uses thereof
AU6550598A (en) Antithrombin protein and dna sequences
GB9606272D0 (en) Gene and peptides
GB9828022D0 (en) Enzyme and DNA sequence encoding same
IL136477A0 (en) Human thyroid protein zsig45 and dna encoding same
EP1026245A4 (de) Antigenes protein und die dafür kodierende nukleinsäure
GB9412000D0 (en) Gene encoding the human 38kda fk-506 binding protein
GB9502480D0 (en) DNA and protein sequences
GB9721358D0 (en) Nucleotide sequences and protein sequences
GB9721357D0 (en) Nucleotide sequences and protein sequences